WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 6 fonti

Abivax seeks to ease safety concerns with new data, boosting shares

Safety concerns tied to Abivax's experimental bowel disease drug tanked company shares just weeks ago. But a new analysis sent them climbing.

Raccontata da

it.euronews.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo2 g fa

Abivax seeks to ease safety concerns with new data, boosting shares

Safety concerns tied to Abivax's experimental bowel disease drug tanked company shares just weeks ago. But a new analysis sent them climbing.

Timeline cronologica

martedì 30 giugno 2026·statnews.com
Abivax seeks to ease safety concerns with new data, boosting shares
Safety concerns tied to Abivax's experimental bowel disease drug tanked company shares just weeks ago. But a new analysis sent them climbing.
martedì 30 giugno 2026·cnbc.com
French biotech stock soars 25% after new data on experimental medicine
Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease.

2 g fa

Abivax rallies 36% as trial data ease safety fears over obefazimod

French biotech company Abivax said new clinical trial data supports the safety and effectiveness of its experimental ulcerative colitis treatment.

Leggi questa versione → originale

endpoints.news2 g fa

Abivax aims to set cancer concerns with ulcerative colitis drug to rest

Abivax says new Phase 3 data show cancer rates within expected range for its UC drug obefazimod, though Jefferies flags lingering FDA risk.

Leggi questa versione → originale

French biotech stock soars 25% after new data on experimental medicine

Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease.

Leggi questa versione → originale

benzinga.com2 g fa

Why Is Abivax Stock Skyrocketing Tuesday? - Abivax (NASDAQ:ABVX)

Abivax (ABVX) stock skyrockets 36% following strong Phase 3 maintenance data for its ulcerative colitis treatment. Get the latest details.

Leggi questa versione → originale

it.euronews.com2 g fa

Abivax balza del 36%: i dati riducono i timori su obefazimod

La società francese di biotecnologia Abivax ha dichiarato che i nuovi dati degli studi clinici confermano sicurezza ed efficacia del suo trattamento sperimentale contro la colite ulcerosa.

Leggi questa versione → originale

martedì 30 giugno 2026·

euronews.com

Abivax rallies 36% as trial data ease safety fears over obefazimod

French biotech company Abivax said new clinical trial data supports the safety and effectiveness of its experimental ulcerative colitis treatment.

martedì 30 giugno 2026·

it.euronews.com

Abivax balza del 36%: i dati riducono i timori su obefazimod

La società francese di biotecnologia Abivax ha dichiarato che i nuovi dati degli studi clinici confermano sicurezza ed efficacia del suo trattamento sperimentale contro la colite…

martedì 30 giugno 2026·

benzinga.com

Why Is Abivax Stock Skyrocketing Tuesday? - Abivax (NASDAQ:ABVX)

Abivax (ABVX) stock skyrockets 36% following strong Phase 3 maintenance data for its ulcerative colitis treatment. Get the latest details.

martedì 30 giugno 2026·

endpoints.news

Abivax aims to set cancer concerns with ulcerative colitis drug to rest

Abivax says new Phase 3 data show cancer rates within expected range for its UC drug obefazimod, though Jefferies flags lingering FDA risk.